tiprankstipranks
4D Molecular price target lowered to $42 from $46 at BofA
The Fly

4D Molecular price target lowered to $42 from $46 at BofA

BofA lowered the firm’s price target on 4D Molecular (FDMT) to $42 from $46 on Friday and kept a Buy rating on the shares. The firm notes 4D Molecular provided a comprehensive pipeline update highlighting strategic prioritization of the wet age-related macular degeneration/diabetic macular edema and cystic fibrosis programs. 4D Molecular plans to present 52-week data in wAMD on Feb 8 at the AED meeting. BofA thinks the update should provide clarity on the long-term durability and efficacy, which has been a key investor debate. The firm remains encouraged by 4D-150’s differentiated efficacy and safety profile to-date and view the February update as a key de-risking event.

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles